Dr Moncef Slaoui

Moncef Slaoui has been Chairman, Research & Development of GlaxoSmithKline, PLC, since June 2006, with overall responsibility for GSK Vaccines and Oncology businesses. He has spearheaded an overhaul of GSK’s pharmaceutical R&D, resulting in a substantial improvement in productivity. In his previous position in GSK, he engineered the development of a robust vaccines pipeline, including Rotarix, to prevent infantile gastroenteritis; Synflorix, to prevent Pneumococcal disease; Cervarix, to prevent cervical cancer; and Mosquirix, to prevent Childhood Malaria. Dr Slaoui earned a PhD in molecular biology and immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was a professor of immunology at the University of Mons, Belgium. He has authored more than 100 scientific papers and presentations and is a Member of the PhRMA Board of Directors.